病情控制良好的类风湿关节炎患者对减停生物或靶向合成改善病情抗风湿药的看法及其与提供者看法的比较
该研究通过标准化电话调查62例病情控制良好的类风湿关节炎患者及11名提供者,了解其对减停生物或靶向合成改善病情抗风湿药的看法。39例(63%)患者会考虑减停,患者比提供者更倾向于考虑减停(63% vs 36%)。患者与提供者对长期用药及减停的主要担忧相似,均为恶性肿瘤、感染、疼痛加重、复发和功能丧失。
要点
- 62例病情控制良好的类风湿关节炎患者中39例(63%)会考虑减停生物或靶向合成改善病情抗风湿药。
- 患者认为病情控制良好(OR 8.02)和病程较短(OR 0.94)与更倾向于考虑减停相关。
- 年龄较大、使用传统合成改善病情抗风湿药或每日糖皮质激素的患者更不倾向于考虑减停。
主要发现
- 共62例患者和11名提供者完成调查,39例(63%)患者会考虑减停生物或靶向合成改善病情抗风湿药。
- 认为类风湿关节炎控制良好与更倾向于考虑减停相关(OR 8.02,95%CI 2.15-29.99,P=0.002),病程较短亦相关(OR 0.94,95%CI 0.89-0.99,P=0.02)。
- 年龄较大(OR 0.95,95%CI 0.91-1.0,P=0.05)、使用传统合成改善病情抗风湿药(OR 0.25,95%CI 0.07-0.86,P=0.0275)或每日糖皮质激素(OR 0.08,95%CI 0.02-0.44,P=0.0033)与更不倾向于考虑减停相关。
- 患者和提供者对长期使用生物或靶向合成改善病情抗风湿药的主要担忧为恶性肿瘤和感染,对减停的担忧为疼痛加重、复发和功能丧失。
- 患者比提供者更倾向于考虑减停生物或靶向合成改善病情抗风湿药(63% vs 36%)。
关键数值与推荐
- 认为类风湿关节炎控制良好的患者考虑减停的OR为8.02(95%CI 2.15-29.99,P=0.002)。
- 病程较短与考虑减停相关的OR为0.94(95%CI 0.89-0.99,P=0.02)。
- 年龄较大的患者考虑减停的OR为0.95(95%CI 0.91-1.0,P=0.05)。
- 使用传统合成改善病情抗风湿药的患者考虑减停的OR为0.25(95%CI 0.07-0.86,P=0.0275)。
- 每日使用糖皮质激素的患者考虑减停的OR为0.08(95%CI 0.02-0.44,P=0.0033)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We examined patient and providers' perspectives on tapering biologic or targeted synthetic disease modifying antirheumatic drugs (bDMARD or tsDMARD) in well-controlled RA to determine which factors influence their long-term treatment decisions. METHODS: A standardized phone survey was administered to patients with well-controlled RA based on electronic health record review. Providers were also surveyed. Univariate and multivariable regression analysis was performed with odds ratios (OR) and 95% CI. RESULTS: Sixty-two patients and 11 providers completed the survey. In total, 39 (63%) patients would consider a bDMARD/tsDMARD taper. Patients were more likely to consider a taper if they thought their RA was well-controlled (OR 8.02, 95% CI 2.15-29.99, P = 0.002) and of shorter duration (OR 0.94, 95% CI 0.89-0.99, P = 0.02). Patients were less likely to consider a taper if older (OR 0.95, 95% CI 0.91-1.0, P = 0.05), if they were being treated with conventional synthetic DMARDs (OR 0.25, 95% CI 0.07-0.86, P = 0.0275) or daily glucocorticoids (OR 0.08, 95% CI 0.02-0.44, P = 0.0033). Patients' and providers' top concerns about long-term bDMARD/tsDMARD use were malignancy and infection. Their concerns about tapering were worsening pain, flare and loss of function. Patients were more likely to consider a bDMARD/tsDMARD taper than providers (63% vs 36%). CONCLUSION: Patients who have had well-controlled RA are more likely to consider tapering bDMARD/tsDMARD when not being treated with csDMARDs or glucocorticoids. Patients and providers shared similar concerns regarding long-term use and tapering of bDMARD/tsDMARD, but patients were more likely to consider a taper.
引用
- Wiemer N, Webster P, Attur M, et al. Patient perspectives on tapering biologic or targeted synthetic therapy in well-controlled rheumatoid arthritis and comparison with providers' perspectives. Rheumatology (Oxford). 2023. PMID: 37855678. doi:10.1093/rheumatology/kead431
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。